Summit Therapeutics Inc.
Summit Therapeutics Inc. (SMMT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SMMT · as of Sep 30, 2024
Ownership Breakdown
192
Institutional Holders
▲ 58 vs Q2
$1.85B
Total Inst. Value
▲ $1.29B vs Q2
775.37M
Shares Outstanding
freeFloat 13.83%
84.47M
13F Shares Held
▲ 12.30M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SMMT largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BAKER BROS. ADVISORS LP pharmaceutical preparations | 24.42M | 3.36% | 3.36% | $534.90B | Nov 14, 2024 | ▲ 1.20M |
VANGUARD GROUP INC pharmaceutical preparations | 10.95M | 1.51% | 1.51% | $239.73B | Nov 13, 2024 | ▲ 2.13M |
FMR LLC pharmaceutical preparations | 8.30M | 1.14% | 1.14% | $181.84B | Nov 13, 2024 | ▲ 737.7K |
BLACKROCK, INC. pharmaceutical preparations | 8.09M | 1.11% | 1.11% | $177.27B | Nov 13, 2024 | NEW |
PRICE T ROWE ASSOCIATES INC /MD/ pharmaceutical preparations | 5.44M | 74.86% | 74.86% | $119.13B | Nov 14, 2024 | ▲ 3.40M |
STATE STREET CORP pharmaceutical preparations | 3.47M | 47.73% | 47.73% | $75.96B | Nov 14, 2024 | ▼ 654.6K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.10M | 42.66% | 42.66% | $67.90B | Nov 12, 2024 | ▲ 136.0K |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC pharmaceutical preparations | 1.43M | 19.72% | 19.72% | $31.38B | Nov 12, 2024 | ▲ 498.0K |
MILLENNIUM MANAGEMENT LLC pharmaceutical preparations | 1.22M | 16.82% | 16.82% | $26.77B | Nov 14, 2024 | ▼ 720.5K |
ABRDN PLC pharmaceutical preparations | 1.14M | 15.64% | 15.64% | $24.88B | Oct 25, 2024 | NEW |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
28
Increased
+12.82M shares11
New Positions
first time holders11
Decreased
−2.83M shares0
Sold Out
fully exitedNet shares change (top 50)
+9.99M
+12.82M / −2.83M
Net new holders
+28
11 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SMMT insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
4
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
DUGGAN ROBERT W Co-Chief Executive Officer | Jun 4, 2026 | Purchase | 100,000 | $14.60 | $1.46M | 25.82M | Form 4 ↗ |
Zanganeh Mahkam Co-Chief Executive Officer | Jun 4, 2026 | Purchase | 100,000 | $14.60 | $1.46M | 25.82M | Form 4 ↗ |
Soni Manmeet Singh COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $14.43 | $360.8K | 3.12M | Form 4 ↗ |
Soni Manmeet Singh COO and CFO | Jun 4, 2026 | Purchase | 25,000 | $14.46 | $361.5K | 3.10M | Form 4 ↗ |
Anand Bhaskar Chief Accounting Officer | Jan 8, 2026 | Award | 30,000 | $18.83 | $564.9K | 30.0K | Form 4 ↗ |
Zanganeh Mahkam Co-Chief Executive Officer | Jan 2, 2026 | Award | 11,232 | $17.52 | $196.8K | 11.2K | Form 4 ↗ |
DUGGAN ROBERT W Co-Chief Executive Officer | Jan 2, 2026 | Award | 11,232 | $17.52 | $196.8K | 11.2K | Form 4 ↗ |
Booth Robert F. director | Jan 2, 2026 | Award | 35,000 | $17.52 | $613.2K | 35.0K | Form 4 ↗ |
Booth Robert F. director | Jan 2, 2026 | Award | 7,180 | $17.52 | $125.8K | 7.2K | Form 4 ↗ |
Xia Yu director | Jan 2, 2026 | Award | 35,000 | $17.52 | $613.2K | 35.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Summit Therapeutics Inc. (SMMT) is primarily owned by institutional investors, who hold approximately 10.9% of total shares outstanding. Company insiders own approximately 86.17%, while retail and public investors account for the remaining 2.94%.
The largest institutional shareholder of Summit Therapeutics Inc. is BAKER BROS. ADVISORS LP, holding approximately 24.42 million shares — equal to 3.36% of outstanding shares — as of September 30, 2024.
A total of 192 institutional investors currently hold SMMT stock, with a combined institutional value of approximately $1.85 billion as of the most recent 13F filing period.
Frequently asked questions
SMMT ownershipSummit Therapeutics Inc. (SMMT) is primarily owned by institutional investors, who hold approximately 10.9% of shares. The largest shareholder is BAKER BROS. ADVISORS LP with a 3.36% stake. Company insiders hold 86.17%. Data sourced from SEC Form 13F as of September 30, 2024.